Aplastic anemia: pathogenesis and treatment

Onkologie. 1987 Jun;10(3):172-3. doi: 10.1159/000216399.

Abstract

Treatment of severe aplastic anemia (SAA) in Europe between 1970 and 1986 is reviewed. 487 patients received an HLA-identical BMT: results are encouraging and currently suggest a 65% survival. However, many patients cannot be offered this procedure because of the absence of an appropriate donor. Forty-five patients were given a non-HLA identical BMT: results are dependent on the degree of mismatch. Immunosuppression (IS) was given to 509 patients: 50% of these survive. Some mechanisms regulating in vitro hematopoiesis are discussed, together with their relevance in the treatment of SAA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia, Aplastic / blood
  • Anemia, Aplastic / immunology
  • Anemia, Aplastic / therapy*
  • Bone Marrow Transplantation*
  • Genotype
  • Graft Survival
  • HLA Antigens / genetics
  • Hematopoiesis*
  • Humans
  • Immunosuppression Therapy
  • Immunotherapy*

Substances

  • HLA Antigens